GLP-1-based drugs, initially developed for diabetes and later effective in obesity , are now being explored as a potential therapeutic intervention for Alzheimers disease and other neurodegenerative diseases
Understanding the Issue: Drug-Induced Gastroparesis Injury Glucagon-like peptide-1 (GLP-1) receptor agonists, also known as GLP-1 agonists, incretin mimetics, or GLP-1 analogs, are a class of medications used to treat type 2 diabetes (T2DM) and obesity
Published Research and References for Tirzepatide Coskun T, Sloop KW, Loghin C, et al
Consult your healthcare provider before use if you are pregnant, nursing, or have a medical condition
When exploring self-pay options, youll notice a significant price difference between brand-name medications and compounded alternatives: Compounded medications contain the same active ingredients but are prepared by specialized pharmacies rather than manufactured by pharmaceutical companies
Retatrutide is a triple receptor agonist (GLP-1, GIP, and glucagon) that produced 24.2% average weight loss over 48 weeks in Phase 2 trials